Drugs for Fibrous Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 27)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Risedronate |
Approved, Investigational |
Phase 2, Phase 3 |
|
105462-24-6 |
5245 |
Synonyms:
(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
(1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid
(1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid)
105462-24-6
115436-72-1
115436-72-1 (mono-hydrochloride salt)
1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID
1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate
2-(3-Pyridinyl)-1-hydroxyethylidenebisphosphonate
2-(3-Pyridinyl)-1-hydroxyethylidene-bisphosphonate
AC-1295
AC1L1JX6
Acid, risedronic
Acide risédroniqe
Acide risedronique
Acide risedronique [INN-French]
Acido risedronico
Acido risedronico [INN-Spanish]
Acidum risedronicum
Acidum risedronicum [INN-Latin]
Actonel
Actonel 150
Atelvia
Benet
BIDD:GT0010
Bisphosphate risedronate sodium
Bisphosphonate 1
C08233
|
C7H11NO7P2
CHEMBL923
CID5245
D08484
DB00884
DB02782
HMS2090C21
HSDB 7326
I04-0049
LS-171967
MolPort-005-934-614
NE 58019
NE-58095
Ridron
Ridron (TN)
RIS
risedronate
Risedronate
Risedronate sodium
Risedronate sodium, bisphosphate
Risedronic acid
Risedronic acid (INN)
Risedronic acid [INN:BAN]
Risedronic acid, monosodium salt
Risedronsäure
Sodium, bisphosphate risedronate
Sodium, risedronate
UNII-KM2Z91756Z
|
|
2 |
|
Etidronic acid |
Approved |
Phase 2, Phase 3 |
|
2809-21-4, 7414-83-7 |
3305 |
Synonyms:
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(1-Hydroxyethylene)diphosphonate
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylene)diphosphonic acid, tetrapotassium salt
(1-Hydroxyethylidene)bis(phosphonate)
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonate
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonate
(1-hydroxy-ethylidene)diphosphonic acid
(1-Hydroxyethylidene)diphosphonic acid
(Hydroxyethylidene)diphosphonate
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1 Hydroxyethane 1,1 diphosphonate
1 Hydroxyethylidene 1,1 bisphosphonate
1,1 Hydroxyethylenediphosphonate
1,1,1-Ethanetriol diphosphonate
1,1,1-Ethanetriol diphosphonic acid
1,1-Hydroxyethylenediphosphonate
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
1-Hydroxy-1,1-diphosphonoethane
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-hydroxyethane 1,1-diphosphonic acid
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonate
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonate
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylene diphosphonate, disodium
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-bisphosphonic acid
1-Hydroxyethylidene-1,1-diphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonate
Acetodiphosphonic acid
Acide etidronique
acide étidronique
Acide etidronique [INN-French]
acido Etidronico
Acido etidronico
ácido etidrónico
Acido etidronico [INN-Spanish]
acidum etidronicum
Acidum etidronicum
Acidum etidronicum [INN-Latin]
Bio-0708
BPBio1_000997
BRN 1789291
BSPBio_000905
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
CID3305
Cintichem Technetium 99m Hedspa
D02373
|
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Dicalcium ehdp
Dicalcium etidronate
Didronel
Didronel IV
Diphosphonate (base)
Diphosphonate, disodium 1-hydroxyethylene
Diphosphonic acid, hydroxyethylidene
Disodium 1 hydroxyethylene diphosphonate
Disodium 1-hydroxyethylene diphosphonate
Disodium etidronate
EHDP
EHDP, dicalcium
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Ethanehydroxydiphosphonate
Ethanehydroxyphosphate
etidronate
Etidronate
Etidronate disodium
Etidronate Disodium
Etidronate, dicalcium
Etidronate, disodium
Etidronate, sodium
Etidronate, tetrapotassium salt
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HEDSPA
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonate
Hydroxyethanediphosphonic acid
Hydroxyethylidene diphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MolPort-001-786-542
MPI Stannous Diphosphonate
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonate
Oxyethylidenediphosphonic acid
Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
Salt etidronate, tetrapotassium
SMR000038750
Sodium etidronate
SPBio_002826
STK721995
Tetrapotassium salt etidronate
Turpinal SL
UNII-M2F465ROXU
Xidifon
Xidiphon
Xydiphone
|
|
3 |
|
Zoledronic Acid |
Approved |
Phase 3 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
ácido zoledrónico
Aclasta
AKOS005145739
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42446
CGP 42'446
CGP 42446A
CGP-42446
CGP-42'446
CHEBI:46557
CHEMBL924
CID68740
|
D08689
DB00399
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
Novartis brand of zoledronic acid
Novartis brand OF zoledronic acid
NSC721517
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
Zol
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
|
|
4 |
|
Calcium, Dietary |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
calcium channel blockers |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Diphosphonates |
|
Phase 3 |
|
|
|
7 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
8 |
|
Anesthetics |
|
Phase 3 |
|
|
|
9 |
|
Analgesics |
|
Phase 3 |
|
|
|
10 |
|
Calcium |
Nutraceutical |
Phase 2, Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
11 |
|
Alendronate |
Approved |
Phase 2 |
|
66376-36-1, 121268-17-5 |
2088 |
Synonyms:
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-Hydroxybutylidene)bisphosphonate
(4-amino-1-hydroxybutylidene)bisphosphonic acid
(4-amino-1-Hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4 amino 1 Hydroxybutylidene 1,1 biphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-amino-1-Hydroxybutylidene 1,1-biphosphonate
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
66376-36-1
ABDP
AC1L1CW3
Acide alendronique
Acide Alendronique
Acide alendronique [INN-French]
Acide Alendronique [INN-French]
acido Alendronico
Acido alendronico
Acido Alendronico
Acido alendronico [INN-Spanish]
Acido Alendronico [INN-Spanish]
Acidum alendronicum
Acidum Alendronicum
Acidum alendronicum [INN-Latin]
Acidum Alendronicum [INN-Latin]
Adronat
AKOS001015793
alendronate
Alendronate
Alendronate monosodium salt, trihydrate
|
Alendronate sodium
Alendronate Sodium
ALENDRONATE SODIUM
Alendronate sodium hydrate
Alendronic acid
ALENDRONIC ACID
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Aminohydroxybutane bisphosphonate
Arendal
BIDD:GT0180
bisphosphonate, 65
Bisphosphonate, aminohydroxybutane
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
Sodium, alendronate
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
|
|
12 |
|
Testolactone |
Approved, Investigational |
Phase 2 |
|
968-93-4 |
13769 |
Synonyms:
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione
(4AS,4BR,10ar,10BS,12as)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-F]chromene-2,8(4BH)-dione
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
.DELTA.1-Dehydrotestolactone
.DELTA.1-Dehydrotestololactone
.DELTA.1-Testololactone
1 Dehydrotestolactone
1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone
1,2-Dehydrotestololactone
1,2-didehydrotestololactone
1,2-Didehydrotestololactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI)
13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-Oate delta-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-Oate δ-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-Oic acid delta-lactone
13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone
13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-Oic acid δ-lactone
17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione
17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione
1-Dehydrotestolactone
1-dehydrotestololactone
1-Dehydrotestololactone
2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone
3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
968-93-4
AC1L22FS
Bristol myers squibb brand OF testolactone
Bristol Myers Squibb Brand of Testolactone
Bristol-myers squibb brand OF testolactone
Bristol-Myers Squibb Brand of Testolactone
C02197
C19H24O3
CHEBI:9460
CHEMBL1571
CID13769
D00153
|
D013738
DB00894
delta(1)-Dehydrotestolactone
delta(1)-Testolactone
delta(1)-testololactone
Delta(1)-testololactone
Delta(1)-Testololactone
Delta-1-testololactone
D-homo-17a-oxaandrosta-1,4-diene-3,17-dione
D-homo-17a-Oxaandrosta-1,4-diene-3,17-dione
D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione
EINECS 213-534-6
Fludestrin
HSDB 3255
LMST02020084
LS-102968
MolPort-004-286-011
NCI60_001908
NSC 23759
NSC-12173
NSC23759
SQ 9538
SQ-9538
Teolit
Teslac
TESLAC (TN)
Teslak
Testolacton
Testolactona
Testolactona [INN-Spanish]
Testolactone
Testolactone (USP/INN)
Testolactone [USAN:INN]
Testolactonum
Testolactonum [INN-Latin]
Testolattone
Testolattone [DCIT]
UNII-6J9BLA949Q
ZINC04081771
δ(1)-testololactone
Δ1-testololactone
|
|
13 |
|
Anastrozole |
Approved, Investigational |
Phase 2 |
|
120511-73-1 |
2187 |
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
AC1L1D49
AC-4234
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
Anastrazole
Anastrole
Anastrozol
anastrozole
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
Astra brand OF anastrozole
AstraZeneca brand of anastrozole
AstraZeneca brand OF anastrozole
C08159
C090450
C17H19N5
|
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD1033
ZD-1033
Zeneca brand of anastrozole
Zeneca brand OF anastrozole
Zeneca ZD 1033
ZINC00000941
α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
14 |
|
Fulvestrant |
Approved, Investigational |
Phase 2 |
|
129453-61-8 |
104741 17756771 |
Synonyms:
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC1L2XEN
AC-4693
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
|
Faslodex, ICI 182780, Fulvestrant
fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
Ici 182780
ICI-182780
LS-64781
NCGC00164789-02
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
|
|
15 |
|
Denosumab |
Approved |
Phase 2 |
|
615258-40-7 |
|
Synonyms:
615258-40-7
AMG-162
D03684
Denosumab
Denosumab (genetical recombination)
|
Denosumab (genetical recombination) (JAN)
Denosumab (USAN)
Prolia
Xgeva
|
|
16 |
|
Aromatase Inhibitors |
|
Phase 2 |
|
|
|
17 |
|
Hormones |
|
Phase 2 |
|
|
|
18 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
19 |
|
Estrogen Antagonists |
|
Phase 2 |
|
|
|
20 |
|
Estrogen Receptor Antagonists |
|
Phase 2 |
|
|
|
21 |
|
Estrogens |
|
Phase 2 |
|
|
|
22 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
23 |
|
Letrozole |
Approved, Investigational |
Phase 1 |
|
112809-51-5 |
3902 |
Synonyms:
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
Bio-0057
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
DB01006
|
FEM-345
Femara
Fémara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
Letoval
Letrozol
letrozole
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
LS-38788
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
Novartis brand OF letrozole
Novartis Brand of Letrozole
NSC719345
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
|
|
24 |
|
Histamine |
Approved, Investigational |
|
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
5-imidazoleethylamine
5-Imidazoleethylamine
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
|
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Ceplene
Dihydrochloride, histamine
Eramin
Ergamine
Ergotidine
Free histamine
Histamine dihydrochloride
Histamine hydrochloride
HSM
Hydrochloride, histamine
L-Histamin base
L-Histamine
Peremin
Theramine
|
|
25 |
|
Histamine Phosphate |
|
|
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
26 |
|
Fluorodeoxyglucose F18 |
|
|
|
|
|
27 |
|
Radiopharmaceuticals |
|
|
|
|
|
Interventional clinical trials:
(show all 25)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects |
Completed |
NCT01304121 |
Phase 4 |
|
2 |
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone |
Unknown status |
NCT00445575 |
Phase 2, Phase 3 |
risedronate;placebo;risedronate;placebo |
3 |
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome |
Completed |
NCT00017927 |
Phase 3 |
Pegvisomant |
4 |
Non-inferiority Trial of Three Cycles of Zoledronic Acid Versus Percutaneous Thermal Ablation in Osteoid Osteoma |
Suspended |
NCT02739555 |
Phase 3 |
Acide Zoledronique |
5 |
TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL. |
Completed |
NCT01791842 |
Phase 2 |
Tocilizumab;Placebo |
6 |
A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome |
Completed |
NCT00001728 |
Phase 2 |
Fosamax (Alendronate) |
7 |
Testolactone Treatment of Girls With LHRH Analog-Resistant Precocious Puberty Due to Autonomous, Non-Neoplastic Ovarian Estrogen Secretion |
Completed |
NCT00001181 |
Phase 2 |
Testolactone |
8 |
An Open-label Study Evaluating the Safety and Efficacy of Anastrozoleâ„¢ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome |
Completed |
NCT00055302 |
Phase 2 |
Arimidex 1 mg |
9 |
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of Mccune-Albright Syndrome |
Completed |
NCT02743377 |
Phase 1, Phase 2 |
PET |
10 |
An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome |
Active, not recruiting |
NCT00278915 |
Phase 2 |
Fulvestrant |
11 |
An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia |
Enrolling by invitation |
NCT03571191 |
Phase 2 |
Denosumab |
12 |
Effects of the Aromatase Inhibitor Letrozole on Pubertal Progression and Indices of Bone Turnover in Girls With Precocious Puberty and McCune-Albright Syndrome (MAS) |
Completed |
NCT00006174 |
Phase 1 |
Letrozole |
13 |
Molecular Genetic Study of Suspected Cases of Osteogenesis Imperfecta Attending Assiut University Children Hospital |
Unknown status |
NCT03169192 |
|
Zoledronic Acid |
14 |
Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia |
Completed |
NCT02868645 |
|
|
15 |
Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues |
Completed |
NCT00001973 |
|
|
16 |
The Influence of Bisphosphonates in the Oral Cavity in Children |
Completed |
NCT00402064 |
|
|
17 |
Evaluation and Treatment to Improve Bone Quality and Prevent Fractures by the Percutaneous Replacement of Diseased Tissue in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome |
Completed |
NCT00001851 |
|
|
18 |
Histamine Responsiveness in Patients With McCune-Albright Syndrome |
Completed |
NCT00318097 |
|
|
19 |
Epigenetic Regulation of Activity and Severity of Fibrous Dysplasia in Bone: mirDYS Study. |
Recruiting |
NCT03838991 |
|
|
20 |
Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry |
Recruiting |
NCT03231644 |
|
|
21 |
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome |
Recruiting |
NCT00001727 |
|
|
22 |
Computer Guided Contouring of Craniofacial Fibrous Dysplasia Involving Zygoma: a Case Series |
Recruiting |
NCT03852927 |
|
|
23 |
Clinical and Scientific Assessment of Pain and Painful Disorders |
Recruiting |
NCT02707029 |
|
|
24 |
Elucidating Mechanisms of Pain in Adolescent and Adult Fibrous Dysplasia Patients |
Not yet recruiting |
NCT04125862 |
|
|
25 |
Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome |
Withdrawn |
NCT03520153 |
|
|
|